Capsulomics
Capsulomics, Inc.
Capsulomics, Inc., now known as Previse, is a pioneering medical diagnostics company dedicated to the early detection and prevention of esophageal cancer. The firm leverages cutting-edge molecular testing to empower gastroenterologists with critical insights into patient risk profiles for more informed treatment options.
Products & Team
Esopredict
Esopredict is a cutting-edge molecular diagnostic test that assesses the risk of Barrett's esophagus patients progressing to high-grade dysplasia or esophageal adenocarcinoma. By analyzing DNA methylation biomarkers within esophageal tissue samples, it provides a personalized risk assessment for individuals already diagnosed with Barrett's esophagus.
Esopredict addresses the critical challenge of late-stage detection in esophageal cancer by enabling earlier identification of high-risk patients, facilitating timely interventions and personalized treatment strategies.
The threat of late-stage esophageal cancer due to late detection of high-risk patients, leading to poor prognosis and limited treatment options.